首页 > 市场调查报告书 > 製药

治疗药物监测市场规模、份额和成长分析（按产品、技术、药物类别、检体、最终用户和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1897868

治疗药物监测市场规模、份额和成长分析（按产品、技术、药物类别、检体、最终用户和地区划分）－2026-2033年产业预测

Therapeutic Drug Monitoring Market Size, Share, and Growth Analysis, By Product (Consumables, Equipment), By Technology (Immunoassays, Chromatography-Spectrometry), By Drug Class, By Specimen, By End Users, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月26日 | 出版商:

SkyQuest | 英文 199 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球治疗药物监测市场规模预计在 2024 年达到 23.7 亿美元，从 2025 年的 25.7 亿美元增长到 2033 年的 49.1 亿美元，在预测期（2026-2033 年）内复合年增长率为 8.4%。

全球治疗药物监测 (TDM) 市场正逐步復苏，这主要得益于个人化医疗的日益普及以及慢性病管理中对精准药物剂量的需求。癫痫、自体免疫疾病和心血管疾病等慢性病的高发生率凸显了对治疗窗较窄的药物进行持续监测的必要性。预测医学和精准医学的创新正在变革 TDM 领域，尤其关注照护现场和整合人工智慧的数位技术，以实现即时追踪，从而实现及时有效的个人化干预。此外，在监测基础设施不足但对 TDM 设备需求不断增长的发展中市场，TDM 市场具有巨大的成长潜力。然而，高昂的检测成本、多样化的报销政策以及临床实践的地域差异等挑战依然存在，限制了市场的扩张。

全球治疗药物监测市场按产品、技术、药物类别、检体、最终用户和地区进行细分。依产品划分，市场分为软体、耗材及设备。依技术划分，市场分为免疫检测、层析法/光谱法和其他技术。依药物类别划分，市场分为抗癫痫药、抗心律不整药、免疫抑制剂、抗生素和其他药物。依检体划分，市场分为血液和唾液。按最终用户划分，市场分为医院、诊断检查室和研究/学术机构。按地区划分，市场分析涵盖北美、欧洲、亚太、中东/非洲和拉丁美洲。

全球治疗药物监测市场驱动因素

个人化医疗和药物基因组学的日益普及是推动全球治疗药物监测（TDM）市场扩张的主要动力。随着医疗保健从通用治疗策略转向个人通讯协定，TDM 在优化药物疗效和最大限度减少副作用方面发挥关键作用。 TDM 透过确保药物浓度达到适当的治疗水平，尤其对于治疗窗较窄的药物，例如免疫抑制剂、抗癫痫药物和抗癌药，对于推进精准医疗至关重要。此外，癌症、心血管疾病和自体免疫疾病等慢性复杂疾病发生率的不断上升，也日益凸显了在临床实践中实施包含 TDM 的个人化治疗方案的必要性。

限制全球治疗药物监测市场的因素

缺乏标准化的检测通讯协定和测量程序严重阻碍了治疗药物监测市场的发展，导致药物浓度测量和临床解读结果不一致。校准标准、检测平台、检体处理方法和检查室操作规范的差异造成数据碎片化，对治疗准确性产生负面影响。此外，缺乏普遍接受的治疗范围和统一的法规结构也阻碍了临床信心的建立和全球认可。这种不一致限制了数据互通性，使与电子医疗系统的整合变得复杂，削弱了医生的信心，并最终限制了治疗药物监测在医疗机构中的广泛应用和扩充性推广。

全球治疗药物监测市场趋势

全球治疗药物监测 (TDM) 市场正经历显着的变革，这主要得益于不断增长的投资和併购的激增。大型诊断设备製造商和製药公司正积极进行策略性收购，收购专业的 TDM 公司，以利用尖端监控技术并拓展其治疗产品组合。策略联盟的建立进一步推动了这一趋势，增强了研发能力，尤其是在生物分析平台和检测方法创新方面。此外，创业投资对精准诊断技术的日益关注也促进了创新，并为人工智慧增强型 TDM 解决方案的市场准入提供了便利。这种投资动能源自于临床对个人化、以结果为导向的药物给药方案日益增长的需求，预示着市场正在发生动态变化。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Abbott Laboratories
Roche Holding AG
Thermo Fisher Scientific Inc
Siemens Healthineers
Bio-Rad Laboratories
Danaher Corporation
Chromsystems Instruments & Chemicals GmbH
SEKISUI CHEMICAL CO., LTD
Biomerieux SA
Exagen Inc.

结论与建议

简介目录

Product Code: SQMIG35A3020

Global Therapeutic Drug Monitoring Market size was valued at USD 2.37 Billion in 2024 and is poised to grow from USD 2.57 Billion in 2025 to USD 4.91 Billion by 2033, growing at a CAGR of 8.4% in the forecast period (2026-2033).

The Global Therapeutic Drug Monitoring (TDM) Market is witnessing a gradual resurgence, driven primarily by the increased adoption of personalized medicine and the need for precise drug dosages in chronic disease management. The prevalence of chronic conditions, such as epilepsy, autoimmune diseases, and cardiovascular issues, highlights the necessity for ongoing monitoring of narrow therapeutic index drugs. Innovations in predictive and precision medicine are transforming the TDM landscape, with a focus on real-time tracking using point-of-care and digital technologies integrated with AI for faster, tailored interventions. Additionally, there is significant growth potential in developing markets, where the need for TDM instruments is rising amidst inadequate monitoring infrastructure. However, challenges such as high testing costs, varied reimbursement practices, and geographical disparities in clinical practices persist, limiting market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Therapeutic Drug Monitoring market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Therapeutic Drug Monitoring Market Segments Analysis

The global therapeutic drug monitoring market is segmented into product, technology, drug class, specimen, end users and region. By product, the market is software, consumables, and equipment. By technology, the market is segmented into immunoassays, chromatography-spectrometry, and others. By drug class, the market is segmented into antiepileptic drugs, antiarrhythmic drugs, immunosuppressant drugs, antibiotic drugs, and others. By specimen, the market is segmented into blood, and saliva. Based on end user, the market is segmented into hospital, diagnostic labs, and research and academic institutes. By region, the market is analyzed across North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.

Driver of the Global Therapeutic Drug Monitoring Market

The surge in interest surrounding personalized medicine and pharmacogenomics is a significant catalyst for the expansion of the Global Therapeutic Drug Monitoring (TDM) market. As healthcare transitions from generic treatment strategies to tailored protocols, TDM plays an essential role in optimizing drug effectiveness and minimizing adverse effects. By ensuring appropriate therapeutic concentrations for medications, especially those with narrow therapeutic windows like immunosuppressants, antiepileptics, and oncology drugs, TDM is integral to the advancement of precision medicine. Furthermore, the rising incidence of chronic and complex diseases, such as cancer, cardiovascular conditions, and autoimmune disorders, necessitates the adoption of individualized therapeutic plans that increasingly incorporate TDM in clinical practice.

Restraints in the Global Therapeutic Drug Monitoring Market

The lack of standardized test protocols and assay procedures significantly hampers the Therapeutic Drug Monitoring market, leading to inconsistencies in drug concentration measurements and clinical interpretations. Variations in calibration standards, assay platforms, sample processing methods, and laboratory practices result in fragmented data, which adversely impacts therapeutic precision. Additionally, the absence of universally accepted therapeutic ranges and harmonized regulatory frameworks creates obstacles to building clinical trust and achieving global acceptance. This inconsistency restricts data interoperability and complicates integration with electronic health systems, undermining physician confidence and ultimately limiting the broader implementation and scalability of therapeutic drug monitoring across healthcare settings.

Market Trends of the Global Therapeutic Drug Monitoring Market

The global Therapeutic Drug Monitoring (TDM) market is witnessing a significant transformation driven by increased investments and a surge in mergers and acquisitions. Major diagnostics and pharmaceutical companies are strategically acquiring specialty TDM firms to harness cutting-edge monitoring technologies and broaden their therapeutic portfolios. This trend is enhanced by strategic partnerships that bolster research and development capabilities, particularly in bioanalytical platforms and assay innovations. Furthermore, venture capital interest in precision diagnostics is pushing forward advancements, facilitating the entry of AI-enhanced TDM solutions. This investment momentum is propelled by the rising clinical demand for tailored, outcome-focused drug dosing, indicating a dynamic market evolution.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Analysis
Regulatory Analysis
Patent Analysis
Case Studies

Global Therapeutic Drug Monitoring Market Size by Product & CAGR (2026-2033)

Market Overview
Software
Consumables
- Immunoassay-based kits
- Chromatography-based kits
- Others
Equipment
- Immunoassay Analyzers
- Chromatography & MS Detectors
- Others

Global Therapeutic Drug Monitoring Market Size by Technology & CAGR (2026-2033)

Market Overview
Immunoassays
Chromatography-Spectrometry
Others

Global Therapeutic Drug Monitoring Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Antiepileptic Drugs
Antiarrhythmic Drugs
Immunosuppressant Drugs
Antibiotic Drugs
Others

Global Therapeutic Drug Monitoring Market Size by Specimen & CAGR (2026-2033)

Market Overview
Blood
Saliva

Global Therapeutic Drug Monitoring Market Size by End Users & CAGR (2026-2033)

Market Overview
Hospital
Diagnostic labs
Research and Academic Institutes

Global Therapeutic Drug Monitoring Market Size & CAGR (2026-2033)

North America (Product, Technology, Drug Class, Specimen, End Users)
- US
- Canada
Europe (Product, Technology, Drug Class, Specimen, End Users)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Technology, Drug Class, Specimen, End Users)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Technology, Drug Class, Specimen, End Users)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Technology, Drug Class, Specimen, End Users)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chromsystems Instruments & Chemicals GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SEKISUI CHEMICAL CO., LTD
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biomerieux SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exagen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments